Mounjaro vs Ozempic Clinical Differences UK Guide | Complete Nutrition

Weight Loss

Mounjaro vs Ozempic: the clinical differences

Mounjaro (tirzepatide) and Ozempic (semaglutide) differ in mechanism, effectiveness and UK licensing. Mounjaro acts as dual GIP and GLP-1 receptor agonist activating two hormone receptors. Ozempic acts as single GLP-1 receptor agonist. Clinical trials suggest Mounjaro produces greater weight loss (15 to 22 percent) compared to semaglutide (12 to 15 percent at Wegovy doses) over comparable timeframes. Both require once-weekly injection, medical supervision and meeting specific eligibility criteria. In UK, Mounjaro is licensed for both diabetes and weight management. Ozempic licensed only for diabetes - Wegovy is the semaglutide product licensed for weight loss. Decisions between medications should involve GP or specialist consultation matching individual situation rather than marketing or social media information.

Visit the Weight Loss Hub

Updated:
May 2026

Written by:
Dominic Walton, MD

Reading time:
3 min

The full answer

Mounjaro vs Ozempic

Mounjaro and Ozempic differ in specific clinical aspects worth understanding when considering options with medical professionals.

Different mechanisms

Mounjaro: dual GIP and GLP-1 receptor agonist activating two hormone receptors. Ozempic: single GLP-1 receptor agonist. The dual mechanism may produce greater effects on weight and blood sugar regulation. The mechanism difference is fundamental.

Different effectiveness in trials

Mounjaro clinical trials: average 15 to 22 percent weight loss over 72 weeks. Semaglutide weight loss trials (Wegovy doses): average 12 to 15 percent over 68 weeks. Mounjaro typically produces greater weight loss in head-to-head and indirect comparisons.

UK licensing differs

Mounjaro licensed in UK for both type 2 diabetes and weight management. Ozempic licensed only for type 2 diabetes - Wegovy contains semaglutide for weight management. The licensing affects legitimate prescribing options.

Different manufacturers

Mounjaro made by Eli Lilly. Ozempic/Wegovy made by Novo Nordisk. The competing companies driving advancement in this medication category. Both produce substantial weight loss compared to older approaches.

Both administered weekly by injection

Both medications: once-weekly subcutaneous injection. Self-administered after training. Similar administration despite different mechanisms. The weekly injection supports adherence compared to daily medications.

Choosing between options

Practical considerations

Adults considering these medications can approach decision through specific considerations with medical professionals.

Discuss both with GP

Specialist or GP can assess which medication suits individual situation. Diabetes status, BMI, comorbidities, medication interactions all affect choice. The medical assessment essential rather than self-decision.

Consider effectiveness vs cost

Mounjaro generally produces greater weight loss but may cost more. Individual response varies substantially. Match expectations and budget to options. The comparison depends on individual factors.

Match to specific eligibility

Eligibility criteria differ slightly between medications. Some adults eligible for one but not both. The criteria affect access. Discuss specific situation with prescriber.

Consider availability

Mounjaro newer with potentially variable availability. Semaglutide products experienced shortages previously. The supply situation affects practical access. Current availability matters.

Plan for similar lifestyle integration

Both medications work better with dietary changes and exercise. The lifestyle component essential regardless of which medication chosen. Match approach to comprehensive plan rather than medication alone.

Safety

Both require medical supervision

Both Mounjaro and Ozempic are prescription medications requiring medical supervision. Choice between them should involve qualified professionals.

Choice depends on individual situation. GP or specialist assessment determines suitability.
Both have similar side effect profiles. Mostly GI side effects during dose escalation.
Mounjaro may produce greater weight loss. But not always - individual response varies.
Eligibility criteria affect access. Some adults eligible for one but not the other.
Both require long-term planning. Weight regain typically occurs after stopping.

Mounjaro and Ozempic differ in mechanism, effectiveness and UK licensing. Mounjaro: dual GIP and GLP-1 agonist. Ozempic: single GLP-1 agonist. Mounjaro typically produces greater weight loss in trials. In UK, Mounjaro licensed for both diabetes and weight management. Ozempic licensed only for diabetes - Wegovy is semaglutide product for weight loss. Both administered weekly by injection. Both require prescription and medical supervision. Choice should involve GP or specialist consultation matching individual situation. The medications have similar overall approach but specific differences affect optimal choice for individual adults. This article is informational - specific medical decisions should be made with qualified professionals.

For more on weight loss medications our Weight Loss Hub brings every guide together.

Part of the hub

Back to the Weight Loss Hub

This article sits inside our complete weight loss knowledge base covering calorie management, nutrition, exercise, behaviour change, GLP-1 medications, plateaus, maintenance and the practical guidance behind sustainable weight loss. Head back to the hub for the full index.

Visit the Weight Loss Hub

Keep reading

More on weight loss medications

Comparison connects to related topics. what Mounjaro is covers Mounjaro. what Ozempic is covers Ozempic. And common side effects covers side effects.

Frequently asked

Mounjaro vs Ozempic questions

Which is better Mounjaro or Ozempic?

Depends on individual situation. Mounjaro typically produces greater weight loss in trials. Both effective. GP assessment determines suitability based on individual factors. The choice involves multiple considerations beyond just effectiveness.

Is Mounjaro stronger than Ozempic?

Generally more effective in trials. Dual agonist mechanism may produce greater effects than single agonist. Clinical trials show greater average weight loss with Mounjaro. Individual response varies substantially.

Do Mounjaro and Ozempic have different side effects?

Similar profiles. Both produce mostly GI side effects (nausea, vomiting, constipation, diarrhoea) particularly during dose escalation. Specific differences exist but overall profiles similar. Individual response varies.

Can I switch from Ozempic to Mounjaro?

Possibly with medical supervision. Adults switching medications need careful management. Discuss with prescriber. The switch involves specific considerations rather than simple substitution.

Which is cheaper Mounjaro or Ozempic?

Varies. Both similar pricing typically (150 to 300 pounds monthly private). NHS access different. Current pricing varies by provider. The cost matters substantially for long-term decisions.

Can I get either on the NHS?

Yes for adults meeting criteria. NICE guidance covers both medications for specific situations. NHS access limited compared to private prescribing. Discuss with GP for current availability.

Which has more weight regain after stopping?

Both substantial. Adults stopping either medication typically regain most weight. The class of medications produces this pattern. Plan for long-term use or substantial lifestyle changes post-medication regardless of choice.